Abstract
An evolving area of endocrinology practice is the use of incretin-based agents to reduce cardiometabolic risk factors in patients with type 2 diabetes. At a symposium held in conjunction with the American Association of Clinical Endocrinologists' Annual Meeting in Boston, Massachusetts, three experts discussed the evolving understanding of the interrelationship of gut hormonal factors and the neural control of weight and energy homeostasis, including potential therapeutic implications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
